Verve Therapeutics, Inc. financial data

Symbol
VERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Brookline Avenue, Suite 601, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.59K % +5.55%
Debt-to-equity 27.4 % +2.78%
Return On Equity -35.2 % +9.3%
Return On Assets -27.7 % +9.82%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.7M shares +32.8%
Common Stock, Shares, Outstanding 84.6M shares +32.8%
Entity Public Float 940M USD -99.8%
Common Stock, Value, Issued 85K USD +32.8%
Weighted Average Number of Shares Outstanding, Basic 84.6M shares +33.9%
Weighted Average Number of Shares Outstanding, Diluted 84.6M shares +33.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 196M USD +11.8%
General and Administrative Expense 54.8M USD +11.7%
Operating Income (Loss) -227M USD -4.45%
Nonoperating Income (Expense) 29.8M USD +22.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -197M USD -9.49%
Income Tax Expense (Benefit) 308K USD +55.2%
Net Income (Loss) Attributable to Parent -197M USD -2.19%
Earnings Per Share, Basic -2.46 USD/shares +20.4%
Earnings Per Share, Diluted -2.46 USD/shares +20.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 159M USD +103%
Marketable Securities, Current 381M USD -6.3%
Cash, Cash Equivalents, and Short-term Investments 540M USD +11.3%
Assets, Current 556M USD +11.7%
Property, Plant and Equipment, Net 19.6M USD -5.66%
Operating Lease, Right-of-Use Asset 79.9M USD -8.18%
Other Assets, Noncurrent 3.13M USD +105%
Assets 664M USD +8.41%
Accounts Payable, Current 4.64M USD +340%
Accrued Liabilities, Current 21.9M USD -6.35%
Liabilities, Current 42.6M USD +23.3%
Operating Lease, Liability, Noncurrent 60.9M USD -8.7%
Other Liabilities, Noncurrent 118K USD -44.6%
Liabilities 155M USD +2.18%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.14M USD
Retained Earnings (Accumulated Deficit) -693M USD -39.7%
Stockholders' Equity Attributable to Parent 509M USD +10.5%
Liabilities and Equity 664M USD +8.41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.1M USD +12.2%
Net Cash Provided by (Used in) Financing Activities 22.7M USD +1016%
Net Cash Provided by (Used in) Investing Activities -41.6M USD -370%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 84.6M shares +32.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62M USD -95.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 163M USD +96.6%
Deferred Tax Assets, Valuation Allowance 172M USD +57%
Deferred Tax Assets, Gross 197M USD +45.1%
Operating Lease, Liability 71.3M USD -7.23%
Depreciation 6.57M USD +35.1%
Payments to Acquire Property, Plant, and Equipment 433K USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -195M USD -1.46%
Lessee, Operating Lease, Liability, to be Paid 98.1M USD -10.4%
Property, Plant and Equipment, Gross 35M USD +18%
Operating Lease, Liability, Current 10.4M USD +2.47%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.2M USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD +3.13%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26.8M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.5M USD +3.14%
Deferred Tax Assets, Operating Loss Carryforwards 51.3M USD +17.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.9M USD +3.15%
Operating Lease, Payments 2.64M USD -16.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 42.1M USD +29.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%